R. Vyzoukaki

发表

Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma

K. Sfiridaki, M. Alexandrakis, G. Tsirakis, 2014, Tumor Biology.

Activated Protein C-Resistance Determination and Vascular Access Thrombosis in Populations with High Prevalence of Factor V Leiden

M. Alexandrakis, A. Papadopoulou, N. Androulakis, 2015, Nephron.

Bone Marrow Mast Cell Density Correlates with Circulating Biomarkers of Bone Disease in Multiple Myeloma

M. Alexandrakis, G. Tsirakis, A. Papadopoulou, 2016 .

The Impact of Mast Cell Density on the Progression of Bone Disease in Multiple Myeloma Patients

M. Tzardi, M. Alexandrakis, G. Tsirakis, 2016, International Archives of Allergy and Immunology.

Circulating levels of soluble Fas ligand reflect disease progression in multiple myeloma

M. Alexandrakis, G. Tsirakis, C. Pappa, 2014, Medical Oncology.

Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma

K. Sfiridaki, I. Neonakis, M. Alexandrakis, 2015, Journal of Cancer Research and Clinical Oncology.

Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity

M. Alexandrakis, G. Tsirakis, A. Papadopoulou, 2015, Medical Oncology.

Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.

M. Tzardi, M. Alexandrakis, G. Tsirakis, 2015, Leukemia research.

Correlation of Mast Cell Density With Angiogenic Cytokines in Patients With Active Multiple Myeloma.

M. Tzardi, M. Alexandrakis, G. Tsirakis, 2016, Clinical therapeutics.

High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity

A. Alegakis, M. Alexandrakis, A. Papadopoulou, 2015, Tumor Biology.